Table II.
Pathways with P<0.01, based on differentially expressed genes from differentially expressed molecular functions.
| Pathway | Count | P-value | Gene |
|---|---|---|---|
| Ribosome | 55 | 1.27×10−64 | RPL18, RPL19, RPL14, RPL13, RPL15, RPLP2, RPS2, RPS3, RPLP0, RPLP1, FAU, RPL11, RPS4X, RPS18, RPS19, RPL41, RPS16, RPS15, RPS12, RPL3L, RPS4Y1, RPS10, RPS11, RPL27A, RPL35, RPS15A, RPL37, RPL38, RPL39, RPS25, RPL30, RPS27, RPS28, RPS29, RPL7, RPL6, RPL31, RPL9, RPL34, RPL8, RPL3, RPS21, RPS23, RPS24, RPS9, RPL27, RPL23A, RPL24, RPS6, RPS5, RPS8, RPL28, RPL29, RPS7, RPL22 |
| Hypertrophic cardiomyopathy | 15 | 1.09×10−7 | ACTB, LAMA2, ACTC1, DES, MYL2, MYL3, DMD, MYBPC3, MYH7, MYH6, TTN, TPM2, TPM1, TPM4, TGFB2 |
| Dilated cardiomyopathy | 15 | 3.02×10−7 | ACTB, LAMA2, ACTC1, DES, MYL2, MYL3, DMD, MYBPC3, MYH7, MYH6, TTN, TPM2, TPM1, TPM4, TGFB2 |
| Tight junction | 17 | 1.25×10−6 | ACTB, PPP2R1B, PPP2R1A, MYL5, MYL2, EPB41, VAPA, MYLPF, MYH7, ACTN2, MYH6, ACTN3, LLGL1, MYL9, PPP2CA, MYH11, SPTAN1 |
| Focal adhesion | 20 | 4.41×10−6 | EGFR, COL4A4, ACTB, CAV1, COL4A2, MYL5, MYL2, ERBB2, MYLPF, ACTN2, ACTN3, MYL9, LAMA2, LAMA1, LAMA4, LAMC3, BCL2, COMP, LAMC1, LAMB1 |
| Small cell lung cancer | 10 | 6.72×10−4 | COL4A4, LAMA2, LAMA1, LAMA4, COL4A2, LAMC3, BCL2, TP53, LAMC1, LAMB1 |
| ECM-receptor interaction | 10 | 6.72×10−4 | COL4A4, LAMA2, LAMA1, LAMA4, COL4A2, LAMC3, COMP, AGRN, LAMC1, LAMB1 |
| Cardiac muscle contraction | 8 | 7.21×10−3 | ACTC1, MYL2, MYL3, MYH7, MYH6, TPM2, TPM1, TPM4 |
| ABC transporters | 6 | 8.50×10−3 | ABCG8, ABCG5, TAP2, TAP1, ABCG4, ABCG1 |
| Regulation of actin cytoskeleton | 14 | 9.35×10−3 | EGFR, ACTB, MYL5, MYL2, MYLPF, ACTN2, ARPC4, ARPC5, ACTN3, MYL9, ARPC1B, ARPC3, ARPC2, MSN |
ECM, extracellular matrix; ABC transporter, ATP-binding cassette transporter. The Expression Analysis Systematic Explored (EASE) test was used for analysis.